3:33
Allogeneic CD123-targeting CAR T-cell for AML: risks and potential
Marina Konopleva
1:49
Are CAR NK-cells the future of CLL therapy?
William Wierda
3:07
Finding the right targets for CAR T-cell therapy in AML
Marina Konopleva
3:39
CAR T-cells in CLL: the current landscape
William Wierda
1:56
Promising approaches and clinical trials in MDS
David Steensma
3:38
Anti-BCMA CAR T-cells in myeloma: what data do we have so far?
Yi Lin
5:47
Where in the treatment sequence should CAR T-cells be used for myeloma?
Andrew Spencer et al.
9:28
CAR T-cells in myeloma: exploratory targets & payment models
Andrew Spencer et al.
6:20
Myeloma 2018 day 2 round-up: CAR T-cell therapy & drug resistance
Florian Bassermann et al.
10:33
Myeloma 2018 day 1 highlights: precision medicine, epigenetics & novel targets
Keith Stewart et al.
11:40
Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs
Adam Cohen et al.
1:27
Topics of interest from EBMT 2018
Abdul Hamid Bazarbachi
1:39
JACIE: improving the quality of cellular therapy and transplantation
Fermin Sanchez-Guijo
2:51
MRD testing in acute leukemias
Josep-Maria Ribera
1:22
Novel therapies for treating relapsed/refractory ALL
Daniel DeAngelo
2:20
NGS and high sensitivity ddPCR for detecting MRD
Oliver Ottmann
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals